Published: March 2009
Pages: 492
Published by: BioPerspectives

Multiplexed diagnostics are the long-awaited ascendance of ’omics into healthcare. The promise of multiple measurements to characterize complexity is finally being realized. Multiplexed diagnostics, which are combinations of independent measurements or discrete multivariate signatures, are enlightening physicians about improved diagnoses and predictions of responses to treatments and elevating the consistency and efficiency of the entire healthcare system, while all-powerful regulators watch from above with minimal interference. The ascendance of individual tests, however, is fraught with unstable reimbursement and an ever-intensifying storm of competition. On balance, though, the market is uplifting, according to a new report, Multiplexed Diagnostics 2009, published by Select Biosciences and based on analysis by BioPerspectives and Bachmann Consulting. The market is estimated to be more than $1.9 billion in 2008 and is projected to grow to more than $5.8 billion by 2014.

Successful ascendance of individual tests requires a detailed understanding of the market. Multiplexed Diagnostics 2009 explains the unmet needs, trends, regulations, reimbursement, competition, technologies and business strategies. The 492-page report includes a survey of almost 250 respondents, interviews with 9 experts, a detailed database of more than 265 commercial multiplexed diagnostics and a two-tiered quantitative worldwide market model. In addition, the report comes with one hour of consulting (in the form of a conference call) with one of the authors, Dr. Steven Bodovitz, Principal of BioPerspectives, or Dr. Jutta Bachmann, CEO of Bachmann Consulting. To order a copy of the report and begin your enlightenment, please click here.

Report Table of Contents [Downloadable PDF File]

Sample Pages from the Market Report [Downloadable PDF File]

Purchase report >>